NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NextCure (NASDAQ:NXTC) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $3.00 price target on the stock.

NextCure Stock Performance

NXTC opened at $0.64 on Monday. The business’s fifty day moving average is $0.77 and its 200-day moving average is $1.08. The firm has a market cap of $17.94 million, a P/E ratio of -0.31 and a beta of 0.71. NextCure has a 52-week low of $0.64 and a 52-week high of $2.57.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). On average, research analysts predict that NextCure will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of NextCure

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC boosted its stake in NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock valued at $61,000 after buying an additional 22,724 shares in the last quarter. Geode Capital Management LLC boosted its stake in NextCure by 14.2% in the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after buying an additional 27,812 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in NextCure in the fourth quarter valued at about $311,000. Renaissance Technologies LLC boosted its stake in NextCure by 27.9% in the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after buying an additional 113,300 shares in the last quarter. Finally, Tang Capital Management LLC raised its position in NextCure by 7.3% in the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after purchasing an additional 47,614 shares during the last quarter. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.